Global Cell Therapy Biomanufacturing Market 2024-2029

Executive Summary

The market is anticipated to achieve a CAGR of 11.5%, resulting in a value of $16.7 billion by the end of 2029. The growth trajectory of the cell therapy biomanufacturing market is underpinned by a convergence of factors that collectively fuel its expansion and innovation. Foremost among these drivers is the escalating prevalence of chronic and degenerative diseases worldwide, accentuating the urgent need for novel therapeutic interventions. This demand is met by the remarkable strides in cell therapy technologies, marked by breakthroughs in cell engineering, gene editing, and manufacturing processes. These advancements empower researchers and clinicians to effectively harness cells’ regenerative and immunomodulatory properties, offering targeted and personalized treatment modalities for a spectrum of ailments.

Regulatory entities like the FDA and the European Medicines Agency (EMA) have championed initiatives to streamline approval processes, catalyzing the development and commercialization of cell-based therapies. Initiatives like the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and the EMA’s Priority Medicines (PRIME) scheme expedite the translation of promising therapies from bench to bedside, fostering a conducive regulatory environment that incentivizes investment and innovation. Indeed, robust investment and funding streams from diverse sources, including venture capital, pharmaceutical conglomerates, and governmental agencies, underscore the burgeoning interest and confidence in the market’s potential. This financial backing fuels research, development, and clinical trials, propelling the proliferation of novel cell therapy solutions.

The expanding applications of cell therapy across oncology, regenerative medicine, and immune disorders widen the market’s scope, offering multifaceted avenues for growth and therapeutic advancement. Breakthroughs in induced pluripotent stem cell (iPSC) therapy, mesenchymal stem cell (MSC) therapy, and chimeric antigen receptor (CAR) T-cell therapy underscore the versatility and efficacy of cell-based treatments in addressing an array of medical needs. As the industry evolves, collaborative efforts and strategic partnerships between biopharmaceutical companies, academic institutions, research organizations, and contract manufacturing organizations (CMOs) are pivotal in accelerating innovation, knowledge exchange, and technology transfer. By pooling resources, expertise, and infrastructure, stakeholders harness synergies to navigate regulatory complexities, optimize manufacturing processes, and expedite commercialization timelines. In sum, the cell therapy biomanufacturing market is poised for robust expansion. It is propelled by a confluence of factors that collectively shape its growth trajectory, spur innovation, and pave the way for transformative therapies that promise to improve patient outcomes and revolutionize healthcare standards.

Companies Mentioned

• Biosenic
• Bristol-Myers Squibb Co.
• Danaher Corp.
• Iovance Biotherapeutics Inc.
• Lisata Therapeutics
• Lonza
• Merck Kgaa
• Thermo Fisher Scientific Inc.